From: Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study
Previous therapya
Patients, n (%)
Duration of treatment,bmedian (range), mo
Sunitinib
260 (78)
9 (0–63)
Sorafenib
68 (20)
6 (0–48)
Pazopanib
12 (4)
3 (1–11)
Bevacizumabc
41 (12)
6 (0–29)
Cytokinesd
33 (10)
8 (0–113)